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To the editor:
Leu208Val and Ile181Leu variants of cytochrome P450 CYP2C9 are not related to the
acenocoumarol dose requirement in a Spanish population
Cytochrome P450 CYP2C9 is the principal catalyst of warfarin
and acenocoumarol hydroxilation reactions in human liver
microsomes.1 There is a growing interest in the identification of
genetic variants of cytochrome P450 CYP2C9, which can
modify its ability to inactivate warfarin and acenocoumarol,
since a reduced CYP2C9 activity on these drugs would put
patients at risk of over anticoagulation and subsequent bleeding
complications.2 2C9*2 (Arg144Cys) and 2C9*3 (Ile359Leu)
variant alleles of this cytochrome have been associated with
increased sensitivity to warfarin and acenocoumarol.3-6 But the
allelic frequencies for these variants differ considerably among
different ethnic groups: Caucasians carry the 2C9*2 and 2C9*3
variants (8% to 20% and 6% to 10%, respectively) more
frequently than Asians do (0% and 2% to 5%, respectively).7
Recently, Leung et al8 have identified several genetic polymor-
phisms of cytochrome P450 CYP2C9 in a Chinese population.
Two of them, Leu208Val and Ile181Leu, could have importance
in the sensitivity to oral anticoagulant treatment in Chinese
patients. Allele 208Val is more frequent than the Caucasian
wild-type Leu208 in the Chinese population (75% heterozygotes
and 19% homozygotes) and is associated with a lower warfarin
dose requirement, which could explain why the Chinese popula-
tion is more sensitive to warfarin than the Caucasian one. The
Ile181Leu allelic variant was present in 9% of studied patients
in heterozygous form and was associated with a higher warfarin
dose requirement in that population.8
We have studied Leu208Val and Ile181Leu variants in 106
Spanish anticoagulated patients with a stable requirement for
acenocoumarol to keep the international normalized ratio (INR)
between 2 and 3.2 (41 patients required no more than 7 mg/wk
acenocoumarol; 44 patients required between 7 mg/wk and 28
mg/wk; finally, 21 patients required more than 28 mg/wk). The
population is described in detail elsewhere.6 Genotyping for
Leu208Val and Ile181Leu was done by polymerase chain reaction
followed by digestion with restriction enzyme. Primers for genetic
analysis were TGTGCTCCCTGCAATGTGATCTGGTC (for-
ward) and TGGCCTTACCTGGATCCAGGGGCTGGTC (re-
verse). A forced mismatch was included in position 3 from the 3
end of forward primer to create in combination with 527ATTCTT
(polymorphism Ile181Leu) a restriction site for NlaIV. The reverse
primer also has a forced mismatch in position 3 from the 3 end to
create in combination with 608TTGGTG (polymorphism
Leu208Val) a restriction site for Tsp45I.
Neither Leu208Val nor the Ile181Leu variants were detected in any
of the studied patients, indicating that neither of these genetic variants is
involved in the variability of acenocoumarol requirement in this Spanish
population: if these polymorphisms played a significant role in determin-
ing the acenocoumarol dosage in this population, we should have found
some patients carrying the Leu208Val variant in the group with low
acenocoumarol requirement and patients carrying the Ile181Leu variant
in the high-dose group.
In conclusion, we demonstrate that the Leu208Val and the
Ile181Leu polymorphisms of cytochrome P450 CYP2C9 do not
seem to play an important role in sensitivity to acenocoumarol in
the Spanish population. Factors such as 2C9*2 and 2C9*3 variants
of CYP2C9, age, sex, pharmacologic interactions, or associated
diseases do not completely account for the interindividual differ-
ences in sensitivity to anticoagulant treatment. Therefore, it is
probable that unknown genetic variants influencing the coumarin
metabolism, which are perhaps different in different populations,
will be described in the near future.
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